As of November 17, 2025, the average one-year price target for Perspective Therapeutics is $13.41/share. The forecasts range from a low of $5.05 to a high of $21.00. The average price target ...

Great. Thanks, everyone, for joining us. My name is David Dai, one of the biotech analysts here at UBS. It's our great pleasure to have Perspective Therapeutics with us. Joining us, we have Joel ...

Fintel reports that on October 13, 2025, BTIG reiterated coverage of Perspective Therapeutics (NYSEAM:CATX) with a Buy recommendation. Analyst Price Forecast Suggests 182.53% Upside As of September 30 ...

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Perspective Therapeutics ( (CATX)) just ...

The Bitcoin price has seen a nearly 3% dip in the last 24 hours, currently sitting at $112.5k, while most of the crypto industry followed the drop with similar figures. Even among the top 10 largest ...

In a report released on August 22, David Dai from UBS reiterated a Buy rating on Perspective Therapeutics, with a price target of $18.00. The company’s shares closed last Friday at $3.68. Take ...

On Tuesday, Oppenheimer analysts adjusted their outlook on Perspective Therapeutics Inc (NYSE: CATX), reducing the price target to $15 from the previous $16 while sustaining an Outperform rating on ...

Perspective Therapeutics, Inc. (NYSE:CATX – Free Report) – Equities research analysts at Wedbush boosted their Q1 2025 earnings per share (EPS) estimates for Perspective Therapeutics in a report ...

CatX, the digital insurance and reinsurance marketplace backed by Silicon Valley investor Y Combinator, has launched an artificial intelligence-powered parametric platform on its Bermudian-based ...

In a report released today, Nicole Germino from Truist Financial maintained a Buy rating on Perspective Therapeutics (CATX – Research Report). The company’s shares closed last Friday at $4.01. Germino ...

On Friday, Perspective Therapeutics, Inc. (NYSE:CATX) revealed updated interim results from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET. The data will be presented at the 2025 American Society of ...